Bayer's Kidney Drug Shows Efficacy Against Heart Failure in Late-Stage Trial
By Adria Calatayud
Bayer said its Kerendia kidney-disease drug met a primary goal of a late-stage trial by showing efficacy in patients with heart failure.
The German pharmaceutical and agricultural group said Monday that the drug significantly reduced cardiovascular death and total heart-failure events compared to placebo in addition to usual therapy in a phase 3 clinical study. The drug was well tolerated in the trial, the company added.
Bayer said it would discuss the trial data with health authorities regarding an application of marketing authorization for the condition.
Finerenone, commercialized as Kerendia and Firialta, is already approved for the treatment of adult patients with chronic kidney disease linked to type 2 diabetes in more than 90 countries, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
August 05, 2024 03:04 ET (07:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States